About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Vemurafenib (Zelboraf) for metastatic melanoma, brentuximab vedotin (Adcetris) for Hodgkin’s lymphoma and anaplastic large-cell lymphoma, and icatibant (Firazyr) for acute attacks of hereditary angioedema
Marvin M. Goldenberg, PhD, RPh, MS
Health Care and Law
Medication errors often occur because pharmacists are not following the basic principles of prescription filling. In this month’s column, the authors discuss the importance of training, maintaining concentration during the dispensing process, and focusing on the “five rights” to improve safety for patients.
F. Randy Vogenberg, RPh, PhD; and David Benjamin, PhD
A Review of Currently Available Vaccines
Nine influenza vaccines are currently on the market. The author discusses the various types and dosage forms along with CDC recommendations and considerations for special populations.
Lisa R. Clayville, PharmD
Therapeutic or Toxic?
The FDA regulates DTC pharmaceutical advertising, but critics say that the rules are too relaxed and inadequately enforced. Although there have been calls to ban the ads altogether, remedies to maximize the benefits and minimize the risks have also been proposed.
C. Lee Ventola, MS
Medicare’s Hands Are Tied ... at Least Initially
Given the fact that pharmacists already account for significant health care cost savings, there has been a lot of unhappiness about their omission from the ACO experiment.
Avoiding problems with insulin pen injectors in the hospital
Matthew Grissinger, RPh, FASCP
California Pharmacists Initiate Lawsuits
The Supreme Court must decide whether pharmacists can challenge state laws, pre-empting federal law, that have reduced Medicaid payments to health care providers.
FDA approvals, drug indications, and updates
The Eighth Angiotensin II Receptor Blocker
Azilsartan medoxomil (Edarbi), the eighth angiotensin II receptor blocker for hypertension
Jocelyn D. Jones, PharmD, BCPS; Sylvia H. Jackson, PharmD, MEd, CDE; Carmen Agboton, PharmD; and Tonya S. Martin, PharmD, CGP, MAEd